Original Articles Research Group Personalized Medicine
|
|
- Wilfrid Todd
- 8 years ago
- Views:
Transcription
1 Original Articles Research Group Personalized Medicine (only published papers in international peer reviewed journals during the last 5 years) 1. Binkhorst L., Bannink M., de Bruijn P., Ruit J., Droogendijk H.J., van Alphen R.J., den Boer T.D., Lam M.H., Jager A., van Gelder T, and Mathijssen R.H.J. Augmentation of endoxifen exposure in tamoxifen-treated women following SSRIswitch. Clin. Pharmacokinet. (Epub October 2015). 2. Van Soest R.J., Nieuweboer A.J., de Morrée E.S., Chitu D., Bergman A.M., Goey S.H., Bos M.M.E.M., van der Meer N., Hamberg P., de Wit R., and Mathijssen R.H.J. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur. J. Cancer (Epub August 2015). 3. Huisman S.A., de Bruijn P., Moghaddam-Helmantel I.M., IJzermans J.N.M., Wiemer E.A.C., Mathijssen R.H.J., and de Bruin R.W.F. Fasting protects against the side-effects of irinotecan treatment but does not abrogate anti-tumor activity in mice. Br. J. Pharmacol. (Epub August 2015). 4. Nieuweboer A.J.M., Smid M., de Graan A.J.M., Elbouazzaoui S., de Bruijn P., Eskens F.A.L.M., Hamberg P., Martens J.W., Sparreboom A., de Wit R., van Schaik R.H.N., and Mathijssen R.H.J. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Pharmacogenomics J. (Epub September 2015). 5. Diekstra M.H.M., Liu X., Swen J.J., Boven E., Castellano D., Gelderblom H., Mathijssen R.H.J., Rodríguez-Antona C., García-Donas J., Rini B.I., and Guchelaar H.J. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur. J. Clin. Pharmacol. 71 (12): , Onstenk W., Sieuwerts A.M., Kraan J., Van M., Nieuweboer A.J.M., Mathijssen R.H.J., Hamberg P., Meulenbeld H.J., de Laere B., Dirix L.Y., van Soest R.J., Lolkema M.P.J.K., Martens J.W.M., van Weerden W.M., Jenster G.W., Foekens J.A., de Wit R., and Sleijfer S. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur. Urol. 68 (6): , Crona D.J., Ramirez J., Qiao W., de Graan A.-J.M., Ratain M.J., van Schaik R.H.N., Mathijssen R.H.J., Rosner G.L., and Innocenti F. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. (Epub April 2015). 8. Lankhorst S., Baelde H.J., Kappers M.H.W., Smedts F.M.M., Hansen A., Clahsen-van Groningen M.C., Sleijfer S., Mathijssen R.H.J., Danser A.H.J., and van den Meiracker A.H. Greater sensitivity of blood pressure than renal toxicity to tyrosine-kinase receptor inhibition with sunitinib.
2 Hypertension 66 (3): , Oosten A.W., Oldenmenger W.H., Mathijssen R.H.J., and van der Rijt C.C.D. A systematic review of studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J. Pain 16 (10): , De Graan A.J.M., Sparreboom A., de Bruijn P., de Jonge E., van der Holt B., Wiemer E.A.C., Verweij J., Mathijssen R.H.J., and van Schaik R.H.N. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. Br. J. Clin. Pharmacol. 80 (3): , Diekstra M.H.M., Swen J.J., Boven E., Castellano D., Gelderblom H., Mathijssen R.H.J., Rodríguez-Antona C., García-Donas J., Rini B.I., and Guchelaar H.J. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur. Urol. 68 (4): , Binkhorst L., Kloth J.S.L., de Wit A.S., de Bruijn P., Lam M.H., Chaves-Machado I., Burger H., van Alphen R.J., Hamberg P., van Schaik R.H.N., Jager A., Koch B.C.P., Wiemer E.A.C., van Gelder T., van der Horst G.T.J., and Mathijssen R.H.J. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res. Treat. 152 (1): , Drooger J.C., Jager A., Lam M.H., den Boer M.D., Sleijfer S., Mathijssen R.H.J., and de Bruijn P. Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. J. Pharm. Biomed. Anal. 114: , Burger H., den Dekker A.T., Segeletz S., Boersma A.W.M., de Bruijn P., Debiec- Rychter M., Taguchi T., Sleijfer S., Sparreboom A., Mathijssen R.H.J., and Wiemer E.A.C. Lysosomal sequestration determines intracellular imatinib levels. Mol. Pharm. 88 (3): , Nieuweboer A.J.M., de Morree E.S., de Graan A.J.M., Sparreboom A., de Wit R., and Mathijssen R.H.J. Inter-patient variability in docetaxel pharmacokinetics: a review. Cancer Treat. Rev. 41 (7): , Kloth J.S.L., Binkhorst L., de Wit A.S., de Bruijn P., Hamberg P., Lam M.H., Burger H., Chaves-Machado I., Wiemer E.A.C., van der Horst B.T.J., and Mathijssen R.H.J. Relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence. Clin. Pharmacokinet. 54 (8): , Van Soest R.J., de Morrée E.S., Kweldam C.F., de Ridder C.M.A., Wiemer E.A.C., Mathijssen R.H.J., de Wit R., and van Weerden W.M. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur. Urol. 67 (6): , 2015.
3 18. Kraff S., Nieuweboer A.J.M., Mathijssen R.H.J., Baty F., de Graan A.J.M., van Schaik R.H.N., Jaehde U., and Joerger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother. Pharmacol. 75 (5): , Kloth J.S.L., Pagani A., Verboom M.C., Malovini A., Napolitano C., Kruit W.H.J., Sleijfer S., Steeghs N., Zambelli A., and Mathijssen R.H.J. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br. J. Cancer 112 (6): , Van Leeuwen R.W.F., Jansman F.G.A., van den Bemt P.M.L., de Man F., Piran F., Vincenten I., Jager A., Rijneveld A.W., Brugma J.-D., Mathijssen R.H.J., and van Gelder T. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann. Oncol. 26 (5): , Binkhorst L., Mathijssen R.H.J., Jager A., and van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat. Rev. 41 (3): , Oza A., Cibula D., Oaknin Benzaquen A., Poole C., Mathijssen R.H.J., Sonke G.S., Colombo N., Špaček J., Vuylsteke P., Hirte H., Mahner S., Plante M., Schmalfeldt B., Mackay H., Rowbottom J., Lowe E.S., Dougherty B., Barrett J.C., and Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16 (1): 87-97, Lanvers-Kaminsky C., Sprowl J.A., Malath I., Deuster D., Eveslage M., Schlatter E., Mathijssen R.H.J., Boos J., Jürgens H.-J., am Zehnhoff-Dinnesen A.G., Sparreboom A., and Ciarimboli G. Human OCT2 variant c.808g>t confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 16 (4): , Hamberg P., Mathijssen R.H.J., de Bruijn P., Leonowens C., van der Biessen D., Eskens F.A.L.M., Sleijfer S., Verweij J., and de Jonge M.J.A. Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. Cancer Chemother. Pharmacol. 75 (2): , Toxopeus E.L.A., Talman S., van der Gaast A., Spaander V.M.C.W., van Rij C.M., Krak N.C., Biermann K., Tilanus H.W., Mathijssen R.H.J., van Lanschot J.J.B., and Wijnhoven B.P.L. Induction chemotherapy followed by surgery for advanced oesophageal cancer. Eur. J. Surg. Oncol. 41 (3): , Van Pelt-Sprangers J.M., Geijteman E.C.T., Alsma J., Boere I.A., Mathijssen R.H.J., and Schuit S.C.E. Oromandibular dystonia: a serious side effect of capecitabine.
4 BMC Cancer 15 (1): 1132, Yu H., Steeghs N., Kloth J.S.L., de Wit D., van Hasselt J.G.C., van Erp N.P., Beijnen J.H., Schellens J.H.M., Mathijssen R.H.J., and Huitema A.D.R. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU Br. J. Clin. Pharmacol. 79 (5): , Lankhorst S., Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., Sleijfer S., Mathijssen R.H.J., Baelde H.J., Danser A.H.J., and van den Meiracker A.H. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: Preclinical study. Hypertension 64 (6): , Van der Biessen A.J., Burger H., de Bruijn P. Lamers C., Naus N., Loferer H., Wiemer E.A.C., Mathijssen R.H.J., and de Jonge M.J.A. Phase I study of RGB , a novel, multi-targeted cyclin-dependent kinase inhibitor in patients with solid tumors. Clin. Cancer Res. 20 (18): , Van Leeuwen R.W.F., van Gelder T., Mathijssen R.H.J., and Jansman F.G.A. Drug-drug interactions with tyrosine kinase inhibitors: a clinical perspective. Lancet Oncol. 15 (8): e315-e326, Diekstra M.H.M., Klümpen H.J., Lolkema M.P.J.K., Yu H., Kloth J.S.L., Gelderblom A.J., van Schaik R.H.N., Gurney H., Swen J.J., Huitema A.D.R., Steeghs N., and Mathijssen R.H.J. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU Clin. Pharmacol. Ther. 96 (1): 81-89, Mathijssen R.H.J., Sparreboom A., and Verweij J. Determining the optimal dose in the development of anti-cancer agents. Nat. Rev. Clin. Oncol. 11 (5): , Hu S., Mathijssen R.H.J., de Bruijn P., Baker S.D., and Sparreboom A. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br. J. Cancer 110 (4): , Nieuweboer A.J.M., Hu S., Gui C., Hagenbuch B., Ghobadi Moghaddam-Helmantel I.M., Gibson A.A., de Bruijn P., Mathijssen R.H.J., and Sparreboom A. Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res. 74 (11): , Ter Heine R., Binkhorst L., de Graan A.J.M., de Bruijn P., Beijnen J.H., Mathijssen R.H.J., and Huitema A.D.R. Population pharmacokinetic modeling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. Br. J. Clin. Pharmacol. 79 (3): , Kloth J.S.L., Klümpen H.J., Yu H., Eechoute K., Samer C.F., Kam B.L.R., Huitema A.D.R., Daali Y., Zwinderman A.H., Balakrishnar B., Bennink R.J., Wong M., Schellens J.H.M., Mathijssen R.H.J., and Gurney H.
5 Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clin. Pharmacokin. 53 (3): , Schiavon G., Ruggiero A., Bekers D.J., Barry P.A., Sleijfer S., Kloth J., Krestin G.P., Schöffski P., Verweij J., and Mathijssen R.H.J. The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. Eur. J. Cancer 50 (5): , Bins S., Ratain M.J., and Mathijssen R.H.J. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin. Pharmacol. Ther. 95 (4): , Hollestein L.M., van Herk-Sukel M.P.P., Ruiter R.T., de Vries E., Mathijssen R.H.J., Wiemer E.A.C., Stijnen T., Coebergh J.-W.W., Lemmens V.E.P.P., Herings R.M.C., Stricker B.H.Ch., and Nijsten T. Incident cancer risk after the start of aspirin use: Results from a Dutch populationbased cohort study of low dose aspirin users. Int. J. Cancer 135 (1): , Van Jaarsveld M.T.M., Wouters M.D., Boersma A.W.M., Smid M., van IJcken W.F., Mathijssen R.H.J., Hoeijmakers J.H., Martens J.W.M., van Laere S., Wiemer E.A.C., and Pothof J. DNA damage responsive micrornas misexpressed in human cancer modulate therapy sensitivity. Mol. Oncol. 8 (3): , Gits C.M.M., van Kuijk P.F., Jonkers M.B.E., Smid M., van IJcken W.F., Coindre J.-M., Chibon F., Verhoef C., Mathijssen R.H.J., den Bakker M.A., Verweij J., Sleijfer S., and Wiemer E.A.C. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate mir-145 and mir-451 as tumor suppressors. Int. J. Cancer 135 (2): , Lankheet N.A.G., Kloth J.S.L., Gadellaa-van Hooijdonk C.G.M., Cirkel G.A., Mathijssen R.H.J., Lolkema M.P.J.K., Schellens J.H.M., Voest E.E., Sleijfer S., de Jonge M.J.A., Haanen J.B., Beijnen J.H., Huitema A.D.R., and Steeghs N. Pharmacokinetically-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors. Br. J. Cancer 110 (10): , Gits C.M.M., van Kuijk P.F., de Rijck J.C.W.M., Muskens N., Jonkers M.B.E., van IJcken W.F., Mathijssen R.H.J., Verweij J., Sleijfer S., and Wiemer E.A.C. MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microrna mediated regulation of HIF3. BMC Cancer 14 (1): 429, Hamberg P., Boers-Sonderen M.J., van der Graaf W.T., de Bruijn P., Suttle A.B., Eskens F.A., Verweij J., van Herpen C.M., and Sleijfer S. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br. J. Cancer 110 (4): , 2014.
6 45. Van Soest R.J., van Royen M.E., de Morrée E.S., Moll J.M., Teubel W., Wiemer E.A.C., Mathijssen R.H.J., de Wit R., and van Weerden W.M. Preclinical evidence for cross-resistance between taxanes and abiraterone in castrationresistant prostate cancer. Eur. J. Cancer 49 (18): , Van Jaarsveld M.T.M., Blijdorp I.C.J., Boersma A.W.M., Pothof J., Mathijssen R.H.J., Verweij J., and Wiemer E.A.C. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. Eur J. Cancer 49 (2): , Elens L., Nieuweboer A.J.M., Clarke S.J., Charles K.A., de Graan A.-J.M., Haufroid V., Mathijssen R.H.J., and van Schaik R.H.N. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 14 (2): , Elens L., Nieuweboer A.J.M., Clarke S.J., Charles K.A., de Graan A.J.M., Haufroid V., van Gelder T., Mathijssen R.H.J., and van Schaik R.H.N. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet. Genomics 23 (3): , Oudijk L., Gaal J., Korpershoek E., van Nederveen F.H., Kelly L., Schiavon G., Verweij J., Mathijssen R.H.J., den Bakker M.A., Oldenburg R.A., van Loon R.L.E., O Sullivan M.J., de Krijger R.R., and Dinjens W.N.M. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod. Pathol. 26 (3): , Van Leeuwen R.W.F., Brundel D.H., Neef C., van Gelder T., Mathijssen R.H.J., Burger D.M., and Jansman F.G.A. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br. J. Cancer 108 (5): , Van der Biessen A.J., Cranendonk M.A., Schiavon G., van der Holt B., Wiemer E.A.C., Eskens F.A.L.M., Verweij J., de Jonge M.J.A., and Mathijssen R.H.J. Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist 18 (3): , De Graan A.J.M., Elens L., Sprowl J., Sparreboom A., Friberg L.E., van der Holt B., de Raaf P.J., de Bruijn P., Engels F.K., Eskens F.A.L.M., Wiemer E.A.C., Verweij J., Mathijssen R.H.J., and van Schaik R.H.N. CYP3A4*22 and systemic exposure affect paclitaxel-induced dose-limiting neurotoxicity. Clin. Cancer Res. 19 (12): , Binkhorst L., Mathijssen R.H.J., van Herk-Sukel M.P.P., Bannink M., Jager A., Wiemer E.A.C., and van Gelder T. Unjustified prescribing of CYP2D6 inhibiting SSRI s in women treated with tamoxifen. Breast Cancer Res. Treat. 139 (3): , 2013.
7 54. Van der Veldt A.A.M., Lubberink M., Mathijssen R.H.J., Loos W.J., Herder G.J.M., Greuter H.N., Comans E.F., Rutten H.B., Eriksson J., Windhorst A.D., Hendrikse N.H., Postmus P.E., Smit E.F., and Lammertsma A.A. Toward prediction of efficacy of chemotherapy: A proof of concept study in lung cancer patients using [ 11 C]docetaxel and positron emission tomography. Clin. Cancer Res. 19 (15): , Van Jaarsveld M.T.M., Helleman J., Boersma A.W.M., van Kuijk P.F., van IJcken W.F., Despierre E., Vergote I., Mathijssen R.H.J., Berns E.M.J.J., Verweij J., Pothof J., and Wiemer E.A.C. mir-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32 (36): , De Graan A.J.M., Elens L., Smid M., Martens J.M.W., Sparreboom A., Elbouazzaoui S., Nieuweboer A., Wiemer E.A.C., van der Holt B., Verweij J., van Schaik R.H.N., and Mathijssen R.H.J. A pharmacogenetic predictive model for paclitaxel pharmacokinetics based on a DMET platform. Clin. Cancer Res. 19 (18): , Gits C.M.M., van Kuijk P.F., Jonkers M.B.E., Boersma A.W., van IJcken W.F., Wozniak A., Sciot R., Rutkowski P., Schöffski P., Taguchi T., Mathijssen R.H.J., Verweij J., Sleijfer S., Debiec-Rychter M., and Wiemer E.A.C. MiR and mir-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumors. Br. J. Cancer 109 (6): , Sprowl J.A., van Doorn L., Hu S., van Gerven L., de Bruijn P., Li L., Gibson A.A., Mathijssen R.H.J., and Sparreboom A. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin. Pharmacol. Ther. 94 (5): , Kunert A., Straetemans T., Govers C., Lamers C., Mathijssen R.H.J., Sleijfer S., and Debets R. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu (review). Front. Immunol. 4: 363, Schiavon G., Ruggiero A., Schöffski P., van der Holt B., Bekers D.J., Eechoute K., Vandecaveye V., Krestin G.P., Verweij J., Sleijfer S., and Mathijssen R.H.J. Tumor volume as an alternative response measurement for imatinib treated GIST patients. Plos One 7 (11): e48372, De Bruijn P., de Graan A.J.M., Nieuweboer A., Mathijssen R.H.J., Lam M.-H., de Wit R., Wiemer E.A.C., and Loos W.J. Quantification of cabazitaxel in human plasma by liquid chromatography / triplequadrupole mass spectrometry: a practical solution for non-specific binding. J. Pharm. Biomed. Anal. 59 (2): , Ciarimboli G., Lancaster C.S., Schlatter E., Franke R.M., Sprowl J.A., Pavenstädt H., Massmann V., Guckel D., Mathijssen R.H.J., Yang W., Pui C.H., Relling M.V.,
8 Herrmann E., and Sparreboom A. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin. Cancer Res. 18 (4): , Meulenbeld H.J., Mathijssen R.H.J., Verweij J., de Wit R., and de Jonge M.J.A. Danusertib, an aurora kinase inhibitor. Expert Opin. Investig. Drugs 21 (3): , Kuip E.J.M., Zandvliet M.L., Mathijssen R.H.J., and van der Rijt C.C.D. Pharmacological and clinical aspects of immediate release fentanyl preparations: criteria for selection. Eur. J. Hosp. Pharm. 19 (1): 38-40, Sprowl J.A., Gregorc V., Lazzari C., Mathijssen R.H.J., Loos W.J., and Sparreboom A. Associations between ABCC2 polymorphisms with cisplatin disposition and efficacy. Clin. Pharmacol. Ther. 91 (6): , Schiavon G., Eechoute K., Mathijssen R.H.J., de Bruijn P., van der Bol J.M., Verweij J., Sleijfer S., and Loos W.J. Biliary excretion of imatinib and its active metabolite CGP74588 during severe liver dysfunction. J. Clin. Pharmacol. 52 (7): , Binkhorst L., van Gelder T., Loos W.J., de Jongh F.E., Hamberg P., Ghobadi Moghaddam-Helmantel I.M., de Jonge E., Jager A., Seynaeve C., Van Schaik R.H.N., Verweij J., and Mathijssen R.H.J. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin. Pharmacol. Ther. 92 (1): 62-67, De Graan A.J.M., Loos W.J., Friberg L.E., Baker S.D., van der Bol J.M., van Doorn L., Wiemer E.A.C., van der Holt B., Verweij J., and Mathijssen R.H.J. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin. Cancer Res. 18 (16): , De Graan A.J.M., Lancaster C.S., Obaidat A., Hagenbuch B., Elens L., Friberg L.E., de Bruijn P., Hu S., Gibson A.A., Bruun G.H., Corydon T.J., Mikkelsen T.S., Walker A.L., Du G., Loos W.J., van Schaik R.H.N., Baker S.D., Mathijssen R.H.J., and Sparreboom A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin. Cancer Res. 18 (16): , Binkhorst L., van Gelder T., and Mathijssen R.H.J. Individualization of tamoxifen treatment in breast carcinoma. Clin. Pharmacol Ther. 92 (4): , Eechoute K., van der Veldt A.A.M., Oosting S.F., Kappers M.H.W., Wessels J.A.M., Gelderblom H., Guchelaar H.-J., Reyners A.K.L., van Herpen C.M.L., Haanen J.B., Mathijssen R.H.J., and Boven E. Polymorphisms in endothelial nitric oxide synthase (enos) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin. Pharmacol Ther. 92 (4): , 2012.
9 72. Chatelut E., White-Koning M.L., Mathijssen R.H.J., Puisset F., Baker S.D., and Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br. J. Cancer 107 (7): , Eechoute K., Fransson M.N., Reijners A.K.L., de Jong F.A., Sparreboom A., van der Graaf W.T.A., Friberg L., Schiavon G., Wiemer E.A.C., Verweij J., Loos W.J., Mathijssen R.H.J., and de Giorgi U. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin. Cancer Res. 18 (20): , Lancaster C.S., Bruun G.H., Peer C.J., Mikkelsen T.S., Corydon T.J., Gibson A.A., Hu S., Orwick S.J., Mathijssen R.H.J., Figg W.D., Baker S.D., and Sparreboom A. OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin. Pharmacol Ther. 92 (5): , Mathijssen R.H.J., Loos W.J., and Verweij J. Determining the best dose for the individual patient. J. Clin. Oncol. 29 (33): , Loos W.J., de Graan A.-J., de Bruijn P., van Schaik R.H.N., van Fessem M.A.C., Lam M.-H., Mathijssen R.H.J., and Wiemer E.A. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3- methoxymorphinan, and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/ tandem triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 54 (2): , Engels F.K., Loos W.J., van der Bol J.M., de Bruijn P., Mathijssen R.H.J., Verweij J., and Mathôt R.A.A. Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study. Clin. Cancer Res. 17 (2): , Van der Bol J.M., Visser T.J., Loos W.J., de Jong F.A., Wiemer E.A., van Aken M.O., Planting A.S.Th., Schellens J.H.M., Verweij J., and Mathijssen R.H.J. Effects of methimazole on the elimination of irinotecan. Cancer Chemother. Pharmacol. 67: , Eechoute K., Sparreboom A., Burger H., Franke R.M., Schiavon G., Verweij J., Loos W.J., Wiemer E.A.C., and Mathijssen R.H.J. Drug transporters and imatinib treatment: Implications for clinical practice. Clin. Cancer Res. 17 (3): , Van der Veldt A.A., Eechoute K., Gelderblom H., Gietema J., Guchelaar H.J., van Erp N.P., van den Eertwegh A.J.M., Haanen J.B., Mathijssen R.H.J., and Wessels J.A.M. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17 (3): , Van Doorn L., Eskens F.A.L.M., Visser T.J., van der Lugt A., Mathijssen R.H.J., and Peeters R.P.
10 Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21 (2): , Burger H., Loos W.J., Eechoute K., Verweij J., Mathijssen R.H.J., and Wiemer E. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Updates 14: 22-34, Van der Bol J.M., Loos W.J., de Jong F.A., van Meerten E., Konings I.R.H.M., Lam M.H., de Bruijn P., Wiemer E.A.C., Verweij J., and Mathijssen R.H.J. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective open-label cross-over drug-interaction study. Eur. J. Cancer 47 (6): , Klümpen H.-J., Samer C.F., Mathijssen R.H.J., Schellens J.H.M., and Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 37: , Franke R.M., Lancaster C.S., Peer C.J., Gibson A.A., Kosloske A.M., Orwick S.J., Mathijssen R.H.J., Figg W.D., Baker S.D., and Sparreboom A. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin. Pharmacol. Ther. 89 (5): , Konings I.R.H.M., Sleijfer S., Mathijssen R.H.J., de Bruijn P., Ghobadi Moghaddam- Helmantel I.M., van Dam L.M., Wiemer E.A.C., Verweij J., and Loos W.J. Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemother. Pharmacol. 67 (5): , Eechoute K., Franke R.M., Loos W.J., Scherkenbach L.A., Boere I., Verweij J., Gurney H., Kim R.B., Tirona R.G., Mathijssen R.H.J., Sparreboom A. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin. Pharmacol. Ther. 89: , De Graan A.J.M., Teunissen S.F., de Vos F.Y.F.L., Loos W.J., van Schaik R.H.N., de Jongh F.E., de Vos A.I., van Alphen R.J., van der Holt B., Verweij J., Seynaeve C., Beijnen J., and Mathijssen R.H.J. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J. Clin. Oncol. 29 (24): , Steeghs N., Mathijssen R.H.J., Wessels J.A.M., de Graan A.-J., van der Straaten T., Mariani M., Laffranchi B., Comis S., de Jonge M.J.A., Gelderblom H., and Guchelaar H.J. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest. New Drugs 29 (5): , Binkhorst L., Mathijssen R.H.J., Ghobadi Moghaddam-Helmantel I.M., de Bruijn P., van Gelder T., Wiemer E.A.C., and Loos W.J. Quantification of tamoxifen and three of its phase-i metabolites in human plasma by liquid chromatography / triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 56 (5): , 2011.
11 91. Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., de Krijger R.R., Eechoute K., Mathijssen R.H.J., Sleijfer S., Leijten F., Danser A.H.J., van den Meiracker A.H., and Visser T.J. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J. Clin. Endocrinol. Metab. 96 (10): , Eechoute K., van Zonneveld M., van Daele P.L.A., Gerth van Wijk R., and Mathijssen R.H.J. Suppressing effect of sunitinib on allergic rhinitis: Previously undefined side effects with therapeutic potential. J. Clin. Pharmacol. 51 (11): , Van der Bol J.M., de Jong F.A., van Schaik R.H.N., Sparreboom A., van Fessem M.A.C., van de Geijn F.E., van Daele P.L.A., Verweij J., Sleijfer S., and Mathijssen R.H.J. Influence of mannose-binding lectin polymorphisms on irinotecan-related treatment. Oncologist 15 (10): , De Bruijn P., Sleijfer S., Lam M.-H., Mathijssen R.H.J., Wiemer E.A.C., and Loos W.J. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography / tandem triplequadrupole mass spectrometry. J. Pharm. Biomed. Anal. 51: , Van der Bol J.M., Mathijssen R.H.J., Creemers G.J.M., Planting A.S.Th., Loos W.J., Wiemer E.A.C., Friberg L.E., Verweij J., Sparreboom A., and de Jong F.A. A CYP3A4 phenotype based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res. 16 (2): , Burger H., Zoumaro-Djayoon A., Boersma A.W.M., Helleman J., Berns E.M.J.J., Mathijssen R.H.J., Loos W.J., and Wiemer E.A.C. Differential transport of platinum compounds by the human organic cation transporter hoct2 (hslc22a2). Br. J. Pharmacol. 159: , Franke R.M., Kosloske A.M., Lancaster C.S., Filipski K.K., Hu C., Zolk O., Mathijssen R.H.J., and Sparreboom A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl- -Dglucosaminidase. Clin. Cancer Res. 16 (16): , Pander J., Wessels J.A.M., Mathijssen R.H.J., Gelderblom H., and Guchelaar H.J. Pharmacogenetics of tomorrow: the 1+1=3 principle. Pharmacogenomics 11 (7): , Lammers L.A., Mathijssen R.H.J., van Gelder T., Bijl M.J., de Graan A.-J.M., Seynaeve C., van Fessem M.A.C., Berns E.M.J.J., Vulto A.G., and van Schaik R.H.N. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br. J. Cancer 103 (6): , de Jonge M.J.A., Slingerland M., Loos W.J., Wiemer E.A.C., Burger H., Mathijssen
12 R.H.J., Kroep J.R., den Hollander M.A.G., van der Biessen D., Lam M.-H., Verweij J., and Gelderblom H. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer 46 (16): , Letters Soest R.J., de Morrée E.S., Kweldam C.F., de Ridder C.M.A., Wiemer E.A.C., Mathijssen R.H.J., de Wit R., and van Weerden W.M. Reply to Shiota M., and Yokomizo A.: Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur. Urol. (Epub July 2015). 2. Lankhorst S., Mathijssen R.H.J., Danser A.H.J., and van den Meiracker A.H. Reply to Dingemanse J., and Clozel M.: Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib. Hypertension (Epub May 2015). 3. Van Leeuwen R.W.F., Mathijssen R.H.J., Jansman F.G.A., and van Gelder T. Reply to Conde-Estévez D. et al.; Potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method? Ann. Oncol. 26 (6): , Van Leeuwen R.W.F., van Gelder T., Mathijssen R.H.J., and Jansman F.G.A. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-author s reply. Lancet Oncol. 15 (11): e470-e471, Sparreboom A., and Mathijssen R.H.J. Hepatic uptake transporters and docetaxel disposition in mice. Clin. Cancer Res. 20 (15): 4167, Mathijssen R.H.J., de Bruijn P., Eechoute K., and Sparreboom A. Reply to Chatelut E., et al.; Long-term prospective population PK study in GIST patients -- response. Clin. Cancer Res. 19 (4): 950, Koch B.C.P., van Schaik R.H.N., van Gelder T, and Mathijssen R.H.J. Doubt about the feasibility of preemptive genotyping. Clin. Pharmacol. Ther. 93 (3): 233, Burger H., Mathijssen R.H.J., Sparreboom A., and Wiemer E.A.C. Can specific OCT1 inhibitors be used to determine OCT1 transporter activity towards imatinib? Blood 121 (24): , De Bruijn P., Ghobadi Moghaddam-Helmantel I.M., Loos W.J., Mathijssen R.H.J., and Wiemer E.A.C. The issue of non-specific binding of cabazitaxel.
13 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 932C: 74-75, Sprowl J., Mathijssen R.H.J., and Sparreboom A. Can erlotinib ameliorate cisplatin-induced toxicities? J. Clin. Oncol. 31 (27): , De Graan A.J.M., Binkhorst L., Loos W.J., van Schaik R.H.N., Verweij J., and Mathijssen R.H.J. Reply to Opdam F., et al.; Emphasizing the value of phenotyping in patients receiving tamoxifen. J Clin. Oncol. 30 (4): 465, Van Erp N.P., Mathijssen R.H.J., van der Veldt A.A., Haanen J.B., Reyners A.K.L., Eechoute K., Boven E., Wessels J.A.M., Guchelaar H.J., and Gelderblom H. Myelosuppression by sunitinib is flt-3 genotype dependent. Br. J. Cancer 103 (5): , Book chapters Schellens J.H.M., and Mathijssen R.H.J. Chapter 5: Clinical research-methodology in oncology (Dutch; 9 th edition). Oncologie (in press), Schellens J.H.M., and Mathijssen R.H.J. Chapter 5: Clinical research-methodology in oncology (Dutch; 8 th edition). Oncologie , De Jonge M.J.A., Mathijssen R.H.J., and Loos W.J. Chapter 13: Influence of polyfarmacy and age on the systemic exposure to chemotherapy. (Dutch; 1 st edition). Cancer in the Elderly , Mathijssen R.H.J. Chapter 2: The treatment of cancer: what is the correct dose? (Dutch, 23 th edition). Anselmus Colloquium Cancer 26-39, Mathijssen R.H.J., Beckeringh J.J., Durian M., and Schellens J.H.M. Chapter 17: Anti-cancer drugs (Dutch; 26 th edition). Farmacotherapeutisch Kompas 2010
Original Articles Research Group Personalized Medicine
Original Articles Research Group Personalized Medicine (only peer reviewed journals) 1. Kloth J.S.L., Binkhorst L., de Wit A.S., de Bruijn P., Hamberg P., Lam M.H, Burger H., Chaves-Machado I., Wiemer
More informationTargeted therapy in oncology: mechanisms and toxicity
Targeted therapy in oncology: mechanisms and toxicity Neeltje Steeghs Targeted therapy in oncology: mechanisms and toxicity ISBN/EAN: 978-90-9024614-7 Lay-out: Grafisch bureau Christine van der Ven, Voorschoten
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationWhat is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationVictims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationPARP inhibition basic science and clinical challenge. Thomas Helleday, PhD
PARP inhibition basic science and clinical challenge Thomas Helleday, PhD Poly (ADP-ribose) Polymerase 1 (PARP1) Reprinted by permission from Macmillan Publishers Ltd: Rouleau M et al. Nat Rev Cancer 2010;10:293-301
More informationHow To Understand The Effects Of A Drug On Your Health
Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università
More informationEvaluation of the role of gene polymorphisms in anticancer drug efficacy using in vitro models
Group members and Contact details Jacques Robert graduated in medicine from the University of Strasbourg in 1974 and received hi Research projects: The objectives of our group are: (1) to identify preclinical
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationScientific Spring Meeting Friday March 30, 2012
Scientific Spring Meeting Friday March 30, 2012 Dutch Society for Clinical Pharmacology and Biopharmacy Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie PROGRAMME of the SCIENTIFIC MEETING
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationPharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors
Jacqueline SL Kloth Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors Jacqueline SL Kloth Pharmacokinetics and Pharmacodynamics
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationCOMPENDIA TRANSPARENCY TRACKING FORM. Sunitinib malate. Metastatic breast cancer, HER2-negative
COMPENDIA TRANPARENCY TRACKING FORM DRUG: unitinib malate INDICATION: Metastatic breast cancer, HER2-negative COMPENDIA TRANPARENCY REQUIREMENT 1 Provide criteria used to evaluate/prioritize the request
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationNew Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto
New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic
More informationMolecular markers and clinical trial design parallels between oncology and rare diseases?
Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationThe Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D., Chief Scientific Officer, Trevigen, Inc., Gaithersburg, MD For further infomation, please contact: William Booth, Ph.D. Tel: +44 (0)1235
More informationMetastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More informationMédecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
More informationPublic-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationSubject Index. Bariatric surgery, obesity management 134
Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationPharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationTumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationCancer - Therapeutic Process of Rapid proliferating Tumors
Workshop Interdisciplinare radiazioni: biologia, clinica, ambiente e protezione Centro Ricerche Casaccia ENEA Roma, 14 maggio 2009 basse dosi in radioterapia Alessio G. Morganti 1,2,3, Mariangela Massaccesi
More informationWhat s New in Ovarian Cancer Research? Novel Therapeutics for Ovarian Cancer
What s New in Ovarian Cancer Research? Novel Therapeutics for Ovarian Cancer Scott Kaufmann, M.D., Ph.D. Mayo Clinic Division of Oncology Research October 27, 2012 Where we are now. Surgery Front-line
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationClinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents
Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents J. Jack Lee, Ph.D. Department of Biostatistics 3 Primary Goals for Clinical Trials Test safety and
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL
More informationGenetic Testing for Tamoxifen Treatment. Medical Benefit Effective Date: 10/01/12 Next Review Date: 07/13 Preauthorization* No Review Dates: 07/12
Protocol Genetic Testing for Tamoxifen Treatment (20451) Medical Benefit Effective Date: 10/01/12 Next Review Date: 07/13 Preauthorization* No Review Dates: 07/12 The following Protocol contains medical
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationmicrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationAnalytical Specifications RIVAROXABAN
Page 1 of 9 ANALYTE NAME AND STRUCTURE - RIVAROXABAN SYNONYMS Xarelto CATEGORY Anticoagulant TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND Xarelto (rivaroxaban) is an orally
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationINTRODUCTION % Cells of Control % Cells of Control % Cells of Control A B Rapamycin 24 Hour 48 Hour MS-275 24 Hour 48 Hour 120.000 120.000 100.000 100.000 80.000 80.000 60.000 60.000 40.000 40.000
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationProgress in Treating Advanced Triple Negative Breast Cancer
Progress in Treating Advanced Triple Negative Breast Cancer Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Triple Negative Breast Cancer by Subtype
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationDevelopment of Bone Metastases in Men With Prostate Cancer
Development of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become castrate-resistant
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationEvaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric
More informationOsteosarcoma: treatment beyond surgery
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
More informationPublikationsliste Claudia Götz
Publikationsliste Claudia Götz 1. Reinhard,B., Götz, C., and Faillard, H.: Synthesis of N-Acetyl-9-Oacetylneuraminic acid α-p-aminophenylthioketoside and its application as ligand in the affinity chromatography
More informationTargeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
More informationHCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014.
Page 1 HCV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, April 2014. This report summarises interaction studies relating
More informationTherapeutic Drug Monitoring of Tyrosine Kinase Inhibitors
Drug Monitoring Symposium Swiss MedLab 2012 Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Nicolas Widmer, PharmD, PhD Division of Clinical Pharmacology Centre Hospitalier Universitaire Vaudois
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationPhD/MD-CURRICULUM IKP
1. Summer Semester 2009 Focus: Research Topics at the IKP / RBK 06.05.2009 13.05.2009 20.05.2009 27.05.2009 03.06.2009 10.06.2009 17.06.2009 24.06.2009 01.07.2009 08.07.2009 15.07.2009 P1 O. Burk / A.
More informationThe EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
More informationPost-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
More informationSuccesses and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
More informationTargeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms
Targeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms Wolfram Samlowski, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology
ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More information